tiprankstipranks
Trending News
More News >

New Portfolio - New Portfolio

sumeet.jain@gmail.com

New Portfolio
Individual Investor
Ranked #524,980 out of 833,817 TipRanks' Investors
Success Rate
40%
180 out of 452
profitable transactions
Average Return
5.25%
Average return
per transaction
Share this portfolio:

Portfolio Gain

1-Month Return▼ 2.44%
6-Month Return▲ 28.34%
12-Month Return▲ 64.85%
YTD Return▲ 29.62%
Total Return▲ 145.42%

Best Trade

Opened at
Closed at-
Gain▲ 758.21%

Bio

Performance

22.13%0-22.13%
▲ 11.63%
▲ 6.28%
▼ 0.78%
May 2025
▲ 9.25%
▲ 5.14%
▲ 17.13%
Jun 2025
▲ 7.60%
▲ 2.30%
▲ 8.21%
Jul 2025
▲ 2.76%
▲ 2.05%
▲ 4.46%
Aug 2025
▲ 12.88%
▲ 3.56%
▲ 22.13%
Sep 2025
▲ 10.96%
▲ 2.38%
▲ 6.37%
Oct 2025
▼ 3.57%
▲ 0.19%
▼ 9.47%
Nov 2025
▲ 1.45%
▲ 1.32%
▼ 3.37%
Dec 2025
TipRanks AverageS&P 500Investor Portfolio
▲ 11.63%▲ 6.28%▼ 0.78%
▲ 9.25%▲ 5.14%▲ 17.13%
▲ 7.60%▲ 2.30%▲ 8.21%
▲ 2.76%▲ 2.05%▲ 4.46%
▲ 12.88%▲ 3.56%▲ 22.13%
▲ 10.96%▲ 2.38%▲ 6.37%
▼ 3.57%▲ 0.19%▼ 9.47%
▲ 1.45%▲ 1.32%▼ 3.37%

Recent Activity

Company Name
% of Portfolio
Return
No. of Transactions
Last Transaction
Date
Verona Pharma
▲ 552.28%
4
Close
Oct 06, 2025
Tonix Pharma
0%
▼ 32.21%
1
Open
Sep 28, 2025
IO Biotech
0%
▲ 102.19%
1
Open
Sep 28, 2025
Star Bulk Carriers
▼ 5.24%
3
Close
Jun 08, 2025
Coherus Biosciences
▼ 62.94%
16
Close
Jun 08, 2025
Intrusion
▼ 19.45%
14
Close
Jun 08, 2025
Agenus
▼ 67.33%
27
Close
May 18, 2025
Vor Biopharma
▼ 91.16%
10
Close
May 18, 2025
Inhibikase Therapeutics
▼ 9.59%
21
Close
May 04, 2025
Celcuity
▼ 20.89%
3
Close
Apr 06, 2025
ProKidney
▼ 61.65%
13
Close
Apr 06, 2025
Syros Pharmaceuticals
▼ 99.42%
10
Close
Apr 06, 2025
Krystal Biotech
▲ 74.60%
3
Close
Apr 06, 2025
iTeos Therapeutics
▼ 52.10%
7
Close
Apr 06, 2025
Adobe
▼ 11.04%
5
Close
Jan 26, 2025
New Oriental Education Tech
▼ 28.08%
5
Close
Jan 26, 2025
Cellectis SA
▼ 39.97%
6
Close
Jan 26, 2025
Structure Therapeutics, Inc. Sponsored ADR
▼ 19.08%
4
Close
Jan 26, 2025
Core Natural Resources
▼ 7.46%
2
Close
Jan 26, 2025
Arch Resources
▼ 4.98%
5
Close
Jan 13, 2025